Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination With Atezolizumab or Isatuximab Alone in Patients With Advanced Malignancies
Conditions
Interventions
Isatuximab SAR650984
Atezolizumab
Locations
26
United States
Investigational Site Number :8400004
Santa Monica, California, United States
Investigational Site Number :8400007
Boston, Massachusetts, United States
Investigational Site Number :8400002
Houston, Texas, United States
Investigational Site Number :0560001
Brussels, Belgium
Investigational Site Number :0560002
Ghent, Belgium
Investigational Site Number :1240001
Toronto, Ontario, Canada
Start Date
August 6, 2018
Primary Completion Date
May 11, 2022
Completion Date
May 11, 2022
Last Updated
July 10, 2023
NCT03206060
NCT05564390
NCT07541924
NCT07542041
NCT06608446
NCT07025538
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions